BioXcel Therapeutics
Price & Volume
Stats
See more52W Range | $1.29-$48.72 |
Market Cap | $9.5M |
Shares Short | 222,659 |
Financials
See moreRevenue (12 Mos) | $2.2M |
Revenue Growth (YoY) | -2.7% |
Gross Profit (12 Mos) | $123,000 |
Diluted EPS | -$23.51 |
News
See moreYahoo Finance • last month
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Yahoo Finance • 2 months ago
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Yahoo Finance • 2 months ago
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
Yahoo Finance • 2 months ago
BioXcel Therapeutics Announces $14 Million Registered Direct Offering
About
CEO | Dr. Vimal D. Mehta Ph.D. |
CFO | Mr. Richard I. Steinhart MBA |
Address | 555 Long Wharf Drive, New Haven, CT, United States, 06511 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 37 |
